Clinical use of Bevacizumab in treating refractory glaucoma

Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the w...

Descripción completa

Detalles Bibliográficos
Autores principales: Popescu, V, Pricopie, S, Totir, M, Iancu, R, Yasyn, S, Alexandrescu, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397528/
https://www.ncbi.nlm.nih.gov/pubmed/25914729
_version_ 1782366718891393024
author Popescu, V
Pricopie, S
Totir, M
Iancu, R
Yasyn, S
Alexandrescu, C
author_facet Popescu, V
Pricopie, S
Totir, M
Iancu, R
Yasyn, S
Alexandrescu, C
author_sort Popescu, V
collection PubMed
description Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world. The objective of this review is to present the ophthalmic dosage and administration pathways of bevacizumab in treating refractory glaucoma patients. Abbreviations: VEGF = vascular endothelial growth factor, FDA = Food and Drug Administration, AMD = age-related macular degeneration
format Online
Article
Text
id pubmed-4397528
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-43975282015-04-24 Clinical use of Bevacizumab in treating refractory glaucoma Popescu, V Pricopie, S Totir, M Iancu, R Yasyn, S Alexandrescu, C J Med Life Reviews Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world. The objective of this review is to present the ophthalmic dosage and administration pathways of bevacizumab in treating refractory glaucoma patients. Abbreviations: VEGF = vascular endothelial growth factor, FDA = Food and Drug Administration, AMD = age-related macular degeneration Carol Davila University Press 2015 /pmc/articles/PMC4397528/ /pubmed/25914729 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Popescu, V
Pricopie, S
Totir, M
Iancu, R
Yasyn, S
Alexandrescu, C
Clinical use of Bevacizumab in treating refractory glaucoma
title Clinical use of Bevacizumab in treating refractory glaucoma
title_full Clinical use of Bevacizumab in treating refractory glaucoma
title_fullStr Clinical use of Bevacizumab in treating refractory glaucoma
title_full_unstemmed Clinical use of Bevacizumab in treating refractory glaucoma
title_short Clinical use of Bevacizumab in treating refractory glaucoma
title_sort clinical use of bevacizumab in treating refractory glaucoma
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397528/
https://www.ncbi.nlm.nih.gov/pubmed/25914729
work_keys_str_mv AT popescuv clinicaluseofbevacizumabintreatingrefractoryglaucoma
AT pricopies clinicaluseofbevacizumabintreatingrefractoryglaucoma
AT totirm clinicaluseofbevacizumabintreatingrefractoryglaucoma
AT iancur clinicaluseofbevacizumabintreatingrefractoryglaucoma
AT yasyns clinicaluseofbevacizumabintreatingrefractoryglaucoma
AT alexandrescuc clinicaluseofbevacizumabintreatingrefractoryglaucoma

Ejemplares similares